Pacira BioSciences, Inc. stock analysis

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indi

Ticker: PCRX
Exchange: Nasdaq
Sector: Health Care
Industry: Pharmaceuticals

Market evidence and data freshness

The public preview recorded Pacira BioSciences, Inc. at 36.43 USD on 2026-11-05T19:13:09.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2021-11-05 through 2026-10-13 across 1238 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

What should I review before buying Pacira BioSciences, Inc. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.